Published
1 month agoon
By
Adam BeechThe transaction, led by White Fund, is supported by new private investors, as well as the existing investors FPIM-SFPI, Epimède and Chagral Invest.
ETT has developed a triangulation platform, Endomina, that adds therapeutic channels and degrees of freedom for interventional gastroenterology. The platform has been successfully used by physicians during more than 300 procedures.
ETT will use the series D funding to submit a regulatory marketing submission for its medical devices to the Food and Drug Administration (FDA) in the US for soft tissue approximation. ETT also intends to seek further reimbursement within the EU.
The funding will also help to continue R&D efforts into new products and indications, collate evidence on device capabilities, develop a network of centres of excellence and grow and strengthen the organisation.
CEO Alexandre Chau said: With the device’s clinical performance – as outlined in published results by users in the EU over the last few years – we believe that our technology ideally fits patients’ treatment pathways.
“Endo Tools Therapeutics affixed the CE mark to its first medical devices in the EU in 2015. Future FDA clearance will enable us to expand our coverage into the US market and seek wider adoption by healthcare professionals.”
Michel Baijot, chairman of White Fund, said: “We are very pleased to lead this financing round involving FPIM-SFPI, Epimède, Chagral Invest and other private partners and to count Endo Tools Therapeutics as a White Fund investment.
“Endo Tools Therapeutics’ innovative technology could lead to changes in clinical practice. We believe that with the product in development, the impact on patients, the team in place and the market, this will translate into substantial economic value.”
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.